VRTX stock hub
Vertex is a highly profitable, mature compounder with a dominant franchise in cystic fibrosis generating massive free cash flow. The next phase of growth relies on successfully commercializing its pipeline, including CASGEVY for sickle cell disease and novel pain treatments.
What our analysis says
Pulled from the latest published report. The full reasoning lives under /analysis.
Live price
Polled client-side every 30 s; the bare-URL shell stays cacheable for a full day.
Latest headlines
Fetched client-side; each row carries the publisher and the read-out date.
Next earnings
Fetched client-side from the daily earnings-calendar mirror.
Jump into the research surface
These links all point into /analysis/*, so a hub rollback leaves the report reader and legacy redirects live.
Where the current metrics sit
Percentiles come from the backend screener cohort cache for the ticker's country and sector.
Decision checkpoints
A compact product layer over the same report payload.
Does VRTX pay a dividend?
Capital-return profile from the screener mirror.
VRTX stock returns vs the market
Total return (incl. dividends) compared to S&P 500.
Who owns VRTX?
Insider, institutional, and short-interest positioning.
VRTX momentum and risk profile
RSI, moving-average stack, beta, and risk-adjusted return.
VRTX vs. sector cohort
Currency-neutral comparison: P/E, P/S, ROIC, 5Y revenue CAGR, and 1Y total return. Market-cap column appears only when every peer reports in the same currency.
About VRTX
Hub-level FAQ points readers to the deeper analysis pages.
What is the current VRTX stock rating?
Vertex Pharmaceuticals Incorporated is currently shown with Strong Buy in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.
Where can I read the full VRTX analysis?
The full report lives at /stocks/VRTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.
What fair-value range is used for VRTX?
The latest report frames VRTX around $428 to $722. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.
How often is the VRTX page updated?
The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.